Abstract: Pharmaceutical composition comprising growth-hormone releasing peptide 6 (GHRP-6), tartrate buffer at pH 5.0-6.0, and trehalose as stabilizing agent, as well as the use of said composition for the manufacture of a medicament. The invention also provides a kit of parts comprising said pharmaceutical composition and a method of treatment of an individual in need thereof, which entails the administration of a therapeutically effective amount of the pharmaceutical composition comprising of GHRP-6, tartrate buffer at pH 5.0-6.0 and trehalose.

Abstract: The present application provides detectable compounds useful for identifying compounds that bind (e.g., inhibit) MmpL3. Methods of identifying compounds that bind and/or inhibit MmpL3 are also provided.

Abstract: A system and method for automatically updating software on a measurement device includes a mobile computer application downloaded from an application store. A server pushes the application to the application store. A mobile device receives and runs the application. The mobile device connects wirelessly to the measurement device. When connected to the measurement device, the mobile device is prevented from having connections to networks or devices other than the measurement device. The measurement device includes pneumatic measuring equipment to perform calibration and testing on aircraft flight data instruments. The mobile application automatically triggers an update process for software on the measurement device. During the update process, the measuring equipment is not connected to any instruments. The updated software on the measurement device controls presentation of a user interface on the measurement device and controls operation of the measuring equipment.

Abstract: The present application provides detectable compounds useful for identifying compounds that bind (e.g., inhibit) MmpL3. Methods of identifying compounds that bind and/or inhibit MmpL3 are also provided.

Abstract: The invention provides a method of treating pathogenic bacterial infection (e.g., tuberculosis infection) in an animal comprising administering a peptide-based inhibitor of the STAT3-IL10 pathway or a nucleic acid encoding the peptide-based inhibitor to the animal. The invention also provides methods of treating chronic granulomatous disease and Wegener's granulomatosis in an animal comprising administering a peptide-based inhibitor of the STAT3-IL10 pathway or a nucleic acid encoding the peptide-based inhibitor to the animal.

Abstract: A method for forming neuromuscular junctions includes forming functional neuromuscular junctions between motoneurons and muscle cells by co-culturing one or more human motoneurons and one or more rat muscle cells in a substantially serum-free medium. A synthetic mammalian neuromuscular junction includes a human motoneuron functionally linked to a rat muscle cell in a substantially serum-free medium. An artificial substrate may be used to support the one or more neuromuscular junctions.

Abstract: A system and method for automatically updating software on a measurement device includes a mobile computer application downloaded from an application store. A server pushes the application to the application store. A mobile device receives and runs the application. The mobile device connects wirelessly to the measurement device. When connected to the measurement device, the mobile device is prevented from having connections to networks or devices other than the measurement device. The measurement device includes pneumatic measuring equipment to perform calibration and testing on aircraft flight data instruments. The mobile application automatically triggers an update process for software on the measurement device. During the update process, the measuring equipment is not connected to any instruments. The updated software on the measurement device controls presentation of a user interface on the measurement device and controls operation of the measuring equipment.

Abstract: The invention provides a method of treating pathogenic bacterial infection (e.g., tuberculosis infection) in an animal comprising administering a peptide-based inhibitor of the STAT3-IL10 pathway or a nucleic acid encoding the peptide-based inhibitor to the animal. The invention also provides methods of treating chronic granulomatous disease and Wegener's granulomatosis in an animal comprising administering a peptide-based inhibitor of the STAT3-IL10 pathway or a nucleic acid encoding the peptide-based inhibitor to the animal.

Abstract: Compounds derived from imidazo[4,5-c][1,2,6]thiadiazine 2,2-dioxides, for use as a drug or pharmaceutical composition for treatment of parasitic diseases, preferably of diseases caused by parasites of the Trypanosoma genus, and more preferably for treatment of the Chagas disease. Furthermore, the invention also relates to the pharmaceutical compositions comprising said compounds.

Abstract: Compounds derived from imidazo[4,5-c][1,2,6]thiadiazine 2,2-dioxides, for use as a drug or pharmaceutical composition for treatment of parasitic diseases, preferably of diseases caused by parasites of the Trypanosoma genus, and more preferably for treatment of the Chagas disease. Furthermore, the invention also relates to the pharmaceutical compositions comprising said compounds.

Abstract: A method for forming neuromuscular junctions includes forming functional neuromuscular junctions between motoneurons and muscle cells by co-culturing one or more human motoneurons and one or more rat muscle cells in a substantially serum-free medium. A synthetic mammalian neuromuscular junction includes a human motoneuron functionally linked to a rat muscle cell in a substantially serum-free medium. An artificial substrate may be used to support the one or more neuromuscular junctions.